Aldosterone blockade in patients with heart failure and a reduced left ventricular ejection fraction

European Heart Journal

Volumn 30, Issue 4, 2009, Pages 387-388

  Pitt, Bertram ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST;

CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HUMAN; HYPERKALEMIA; NOTE; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ALDOSTERONE ANTAGONISTS; HEART FAILURE; HUMANS; HYPERKALEMIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 62749201459     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp026     Document Type: Editorial

References (15)

1. Albert NM, Yancy CW, Liang L, Hernandez AF, Fonarow GC. Evolving patterns of use of aldosterone inhibition in chronic heart failure; a report from Get with the Guidelines HF. Circulation 2008;118:S798.
2. Pitt B, Bakris G, Ruilope L, DiCarlo L, Mukherjee R; EPHESUS Investigators. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Am Heart J 2008; 118:1643-1650.
3. Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trial. Eur Heart J 2009;30: 469-477. doi:10.1093/eurheartj/ehn543. Published online ahead of print 9 December 2008.
4. Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, Powers B, Samsa GP, Gray RN. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008;148:16-29.
5. Lakhdar R, Al-Mallah MH, Lanfear DE. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail 2008;14:181-188.
6. Banas J. Absence of clinical hypotension with eplerenone in post acute myocardial infarction patients with heart failure and left ventricular systolic dysfunction. Results from Ephesus. Am J Cardiol 2006:SupplA:227A.
7. Mak G, Murphy NF, Ali A, Walsh A, O'Loughlin C, Conlon C, McCaffrey D, Ledwidge M, McDonald K. Multiple neurohumoral modulating agents in systolic dysfunction heart failure: are we lowering blood pressure too much? J Card Fail 2008;14:555-560.
8. Montezano AC, Callera GE, Yogi A, He Y, Tostes RC, He G, Schiffrin EL, Touyz RM. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler Thromb Vasc Biol 2008;28:1511-1518.
9. Clinical Trials.gov. Emphasis-hf NCT00232180.
10. Aldosterone antagonist therapy for adults with heart failure and preserved systolic function. http://www.clinicaltrials.gov. 2007.
11. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456-2467.
12. Palmer BR, Pilbrow AP, Frampton CM, Yandle TG, Skelton L, Nicholls MG, Richards AM. Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. Eur Heart J 2008;29:2489-2496.
13. Pitt B, Ahmed A, Love TE, Krum H, Nicolau J, Cardoso JS, Parkhomenko A, Aschermann M, Corbalán R, Solomon H, Shi H, Zannad F. History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. Hypertension 2008;52:271-278.
14. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003;108: 1831-1838.
15. Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H, Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49:839-845.